KRAS and neoplasm: Overall, our results strengthen a now compelling body of evidence that overturns the earlier belief that oncogenic KRAS mutations are fully constitutive – instead, it is clear that KRAS-driven tumours are driven by signalling input to the activated KRAS oncoprotein.